Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ
-
-
Minnesota
-
Rochester、Minnesota、アメリカ
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ
-
-
-
-
New South Wales
-
Newtown、New South Wales、オーストラリア
-
-
-
-
-
Barcelona、スペイン
-
-
Madrid
-
Majadahonda、Madrid、スペイン
-
-
-
-
Auckland
-
Grafton、Auckland、ニュージーランド
-
-
-
-
Clichy
-
Leclerc、Clichy、フランス
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL
- Individuals with cirrhosis with Child-Pugh score < 10
- Esophageal or gastric varices on endoscopy within 6 months prior to or at screening
- Hepatic Venous Pressure Gradient (HVPG) > 6 mmHg
- Body mass index (BMI) ≥ 18 kg/m^2
- Naïve to all nucleotides/nucleoside treatments for chronic HCV infection
Exclusion Criteria:
- Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
- HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
- Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
- Refractory ascites as defined by requiring paracentesis > twice within 1 month prior to screening
- Active variceal bleeding within 6 months of screening
- Expected survival of < 1 year
- History of hepatorenal, or hepatopulmonary syndrome.
- Evidence of renal impairment (CrCl < 50 mL/min)
- History of major organ transplantation, including liver transplant.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SOF+RBV
Participants will receive SOF+RBV for 48 weeks.
|
RBV 錠剤は、添付文書の体重に基づく推奨用量に従って、1 日の用量を分割して経口投与されます(75 kg 未満 = 1000 mg、75 kg 以上 = 1200 mg)。
SOF 400mg 錠 1 日 1 回経口投与
他の名前:
|
|
実験的:Observation, then SOF+RBV
Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
|
RBV 錠剤は、添付文書の体重に基づく推奨用量に従って、1 日の用量を分割して経口投与されます(75 kg 未満 = 1000 mg、75 kg 以上 = 1200 mg)。
SOF 400mg 錠 1 日 1 回経口投与
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
時間枠:Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
For the Observation/SOF+RBV group, SVR12 during the observational period was defined as HCV RNA < LLOQ for 12 consecutive weeks, any time during the observational period.
|
Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
時間枠:Posttreatment Weeks 4, 24, and 48
|
SVR4, SVR24, and SVR48 were defined as HCV RNA < LLOQ at 4, 24, and 48 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4, 24, and 48
|
|
Percentage of Participants Experiencing On-Treatment Virologic Failure
時間枠:Up to 48 weeks
|
On-treatment virologic failure was defined as:
|
Up to 48 weeks
|
|
Percentage of Participants Experiencing Viral Relapse
時間枠:Up to Posttreatment Week 24
|
Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
|
Up to Posttreatment Week 24
|
|
Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment
時間枠:Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
HVPG closely reflects the degree of portal hypertension in patients with cirrhosis.
The end of treatment for the Observation group was defined as the end of the observation period.
The treatment period for Group 2 was defined as the end of the observation period to the end of the treatment.
Baseline values were the last available values on or prior to first dose date of any study drug.
|
Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
|
Change From Baseline in Child-Pugh-Turcotte (CPT) Score
時間枠:Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. Data are presented as improvement, no change, or worsening in CPT scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in CPT score was defined as having a decrease in CPT score from baseline, no change in CPT score was defined as having no change in CPT score from baseline, and worsening in CPT score was defined as having an increase in CPT score from baseline. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
|
Change From Baseline in Model for End Stage Liver Disease (MELD) Scores
時間枠:Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. Data are presented as improvement, no change, or worsening in MELD scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in MELD score was defined as having a baseline MELD score of 11-15 or 16-20 that changed to 0-10, or a baseline MELD score of 16-20 that changed to 11-15; no change in MELD score was defined as having no change in score group (0-10, 11-15, or 16-20) from baseline; and worsening in MELD score was defined as having a baseline MELD score of 0-10 that changed to 11-15 or 16-20, or a baseline MELD score of 11-15 that changed to 16-20. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。